NCT06709859 2025-07-17
Afatinib Combined With Chemotherapy as Conversion Therapy in Unresectable EGFR Sensitive Mutation-positive Stage III NSCLC
Shandong Public Health Clinical Center
Phase 2 Recruiting
Clinical Trials
9 trialsNCT07069270 2025-07-16
A Study on the First-line Treatment of Small Cell Lung Cancer With Adebrelimab and Vunakizumab and Chemotherapy
Fujian Cancer Hospital
Phase 2 Not yet recruiting
NCT06617936 2025-07-15
Tislelizumab Combined With Recombinant Human Endostatin Combined With Chemotherapy for Unresectable Stage III Non-small Cell Lung Cancer.
Shandong Public Health Clinical Center
Phase 2 Recruiting
NCT06406608 2024-05-09
Patient-derived Organoid Drug Sensitivity Guided Treatment for Drug-resistant Recurrent Non-Small Cell Lung Cancer
Henan Cancer Hospital
Phase NA Recruiting
NCT06231680 2024-03-29
Thalidomide Prevention or Treatment of Camrelizumab-induced Reactive Cutaneous Capillary Endothelial Proliferation (RCCEP)
Henan Cancer Hospital
Phase 2 Unknown
NCT02621333 2021-05-12
Chemotherapy Combined Autologous Cytokine-induced Killer Cells in Naive Stage IV EGFR-wild Type Lung Adenocarcinoma
Henan Cancer Hospital
Phase 2 Terminated
NCT00864331 2013-08-07
Optimization of Treatment of Advanced Nonsmall Cell Lung Cancer Using Radiotherapy and Chemotherapy
International Atomic Energy Agency
Phase 3 Completed
NCT00455936 2010-10-25
First-line Gefitinib Versus Chemotherapy for Lung Adenocarcinoma in Never Smoker
National Cancer Center, Korea
Phase 3 Completed
NCT00452803 2010-07-12
Pre-operative Chemotherapy Versus Concurrent Chemoradiotherapy in N2 Positive IIIA Non Small Cell Lung Cancer (NSCLC)
National Cancer Center, Korea
Phase 2 Unknown